Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Anti-MOG associated myelitis

https://doi.org/10.14412/2074-2711-2020-3-87-92

Full Text:

Abstract

There is now increasing evidence that demyelinating disease with anti-myelin oligodendrocyte glycoprotein (anti-MOG) antibodies is an independent nosological unit. The paper describes a clinical case of anti-MOG associated myelitis at the CI-TXlevel. Differential diagnosis was made between multiple sclerosis, Devic's myelitis optica, and idiopathic transverse myelitis. The clinical, morphopathological, and diagnostic features of anti-MOG associated myelitis are discussed. There are new diagnostic criteria for neuromyelitis optica spectrum diseases (NMOSD), as well as red flags, in the absence of which the diagnosis of NMOSD can be established as a diagnosis of exclusion.

About the Authors

A. I. Isaykin
A.Ya. Kozhevnikov Clinic of Nervous System Diseases, Department of Nervous System Diseases and Neurosurgery, I.M. Sechenov First Moscow State Medical University (Sechenov University) Ministry of Health of Russia
Russian Federation

Alexei Ivanovich Isaykin.

11, Rossolimo St., Build. 1, Moscow 119021.



O. N. Voskresenskaya
A.Ya. Kozhevnikov Clinic of Nervous System Diseases, Department of Nervous System Diseases and Neurosurgery, I.M. Sechenov First Moscow State Medical University (Sechenov University) Ministry of Health of Russia
Russian Federation

11, Rossolimo St., Build. 1, Moscow 119021.



T. I. Kuzminova
A.Ya. Kozhevnikov Clinic of Nervous System Diseases, Department of Nervous System Diseases and Neurosurgery, I.M. Sechenov First Moscow State Medical University (Sechenov University) Ministry of Health of Russia
Russian Federation

11, Rossolimo St., Build. 1, Moscow 119021.



E. V. Ermilova
A.Ya. Kozhevnikov Clinic of Nervous System Diseases, Department of Nervous System Diseases and Neurosurgery, I.M. Sechenov First Moscow State Medical University (Sechenov University) Ministry of Health of Russia
Russian Federation

11, Rossolimo St., Build. 1, Moscow 119021.



O. V. Stezhko
A.Ya. Kozhevnikov Clinic of Nervous System Diseases, Department of Nervous System Diseases and Neurosurgery, I.M. Sechenov First Moscow State Medical University (Sechenov University) Ministry of Health of Russia
Russian Federation

11, Rossolimo St., Build. 1, Moscow 119021.



References

1. Belova AN, Boiko AN, Belova EM. Diagnostic criteria for neuromyelitis optica associated disorders. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2016;116(2):32-40. (In Russ.).

2. Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation. 2019 Dec 28;16(1):280. doi: 10.1186/s12974-019-1594-1.

3. Ramanathan S, Dale RC, Brilot F. Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. 2016 Apr; 15(4):307-24. doi: 10.1016/j.autrev.2015.12.004. Epub 2015 Dec 17.

4. Sato D, Callegaro D, Lana-Peixoto M, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014 Feb 11;82(6):474-81. doi: 10.1212/WNL.0000000000000101. Epub 2014 Jan 10.

5. Kotov AS. Anti-MOG syndrome: two case reports. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(1):84-8. (In Russ.). doi: 10.14412/2074-2711-2019-1-84-88

6. Tolpeeva OA, Zakharova MN. Diagnostic value of antibodies to myelin proteins in demyelinating diseases of the central nervous system. Neirokhimiya. 2017;34(2):108-17. (In Russ.).

7. Lana-Peixoto MA, Talim N. Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes. Biomedicines. 2019 Jun 12;7(2):42. doi: 10.3390/biomedicines7020042.

8. Kim SM, Kim SJ, Lee HJ, et al. Differential diagnosis of neuromyelitis optica spectrum disorders. Ther Adv Neurol Disord. 2017 Jul;10(7): 265-89. doi: 10.1177/1756285617709723. Epub 2017 May 24.

9. Wingerchuk DM, Banwell В, Bennett J, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177-89. doi: 10.1212/WNL.0000000000001729. Epub 2015 Jun 19.

10. Kong Y, Okoruwa H, Revis J, et al. Pain in patientswith transverse myelitis and its relationship to aquaporin. J Neurol Sci. 2016 Sep 15; 368:84-8. doi: 10.1016/j.jns.2016.06.041. Epub 2016 Jun 23.

11. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol. 2014 Mar;71(3):276-83. doi: 10.1001/jamaneurol.2013.5857.

12. Goh C, Desmond PM, Phal PM. MRI in transverse myelitis. J Magn Reson imaging. 2014 Dec;40(6):1267-79. doi: 10.1002/jmri.24563.

13. Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology. 2012 Sep 18;79(12):1273-7. doi: 10.1212/WNL.0b013e31826aac4e. Epub 2012 Aug 22.

14. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012 Jan 19;9:14. doi: 10.1186/1742-2094-9-14.

15. Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016 Sep 27;13(1):280. doi: 10.1186/s12974-016-0718-0.

16. Marignier R, Bernard-Valnet R, Giraudon P, et al. Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity dependent entity. I. 2013 Jun 11;80(24):2194-200. doi: 10.1212/WNL.0b013e318296e917. Epub 2013 May 8.

17. Kim SH, Kim SY, Huh SY, et al. Outcome of repeated rituximab treatment in 81 patients with neuromyelitis optica spectrum disorders. MSJ. 2012;18(Suppl. 4):294.

18. Harmel J, Ringelstein M, Ingwersen J, et al. Interferon-beta-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab. BMC Neurol. 2014 Dec 17;14:247. doi: 10.1186/s12883-014-0247-3.

19. Gelfand JM, Cotter J, Klingman J, et al. Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO. Neurol Neuroimmunol Neuroinflamm. 2014 Oct 9; 1(3):e34. doi: 10.1212/NXI.0000000000000034. eCollection 2014 Oct.

20. Barnett M, Prineas J, Buckland M, et al. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler. 2012 Jan;18(1):108-12. doi: 10.1177/1352458511421185. Epub 2011 Aug 25.

21. Min J, Kim B, Lee K. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler. 2012 Jan;18(1):113-5. doi: 10.1177/1352458511431973. Epub 2011 Dec 6.

22. Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019 Oct 12;394(10206): 1352-63. doi: 10.1016/S0140-6736(19)31817-3

23. Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019 Aug 15;381(7):614-25. doi: 10.1056/NEJMoa1900866.

24. Anti-Myelin-Oligodendrocyte Glycoprotein (MOG) IIFT Instructions for the indirect immunofluorescence test. The EUROIMMUN IIFT, 2018.


For citation:


Isaykin A.I., Voskresenskaya O.N., Kuzminova T.I., Ermilova E.V., Stezhko O.V. Anti-MOG associated myelitis. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(3):87-92. (In Russ.) https://doi.org/10.14412/2074-2711-2020-3-87-92

Views: 29


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)